title: Osteogenesis versus chondrogenesis by BMP-2 and BMP-7 in adipose stem cells.
abstract: Bone morphogenetic proteins (BMPs) initiate, promote, and maintain chondrogenesis and osteogenesis. We hypothesize that BMP-2 induces an osteogenic, and BMP-7 a chondrogenic phenotype in adipose tissue-derived mesenchymal stem cells (AT-MSCs). We compared the effects of a short 15min BMP-2 or BMP-7 (10ng/ml) treatment on osteogenic and chondrogenic differentiation of AT-MSCs. Gene expression was studied 4 and 14 days after BMP-treatment. At day 4 BMP-2, but not BMP-7, stimulated runx-2 and osteopontin gene expression, and at day 14 BMP-7 down-regulated expression of these genes. At day 4 BMP-2 and BMP-7 stimulated biglycan gene expression, which was down-regulated by BMP-7 at day 14. BMP-7 stimulated aggrecan gene expression at day 14. Our data indicate that BMP-2 treatment for 15min induces osteogenic differentiation, whereas BMP-7 stimulates a chondrogenic phenotype of AT-MSCs. Therefore, AT-MSCs triggered for only 15min with BMP-2 or BMP-7 provide a feasible tool for bone and cartilage tissue engineering.
authors.affiliation: Department of Oral Cell Biology, Academic Centre of Dentistry Amsterdam (ACTA)-UvA and Vrije Universiteit, Amsterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Knippenberg
authors.forename: M N
authors.initials: MN
authors.lastname: Helder
authors.forename: B
authors.initials: B
authors.lastname: Zandieh Doulabi
authors.forename: P I J M
authors.initials: PI
authors.lastname: Wuisman
authors.forename: J
authors.initials: J
authors.lastname: Klein-Nulend
mesh_terms: D000273:Adipose Tissue / Q000166:cytology*; D053674:Aggrecans; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D058578:Biglycan; D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D002452:Cell Count; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D020219:Chondrogenesis / Q000187:drug effects*; D011508:Chondroitin Sulfate Proteoglycans / Q000235:genetics; D050659:Core Binding Factor Alpha 1 Subunit / Q000235:genetics; D016326:Extracellular Matrix Proteins / Q000235:genetics; D005786:Gene Expression Regulation / Q000187:drug effects; D006041:Goats; D006801:Humans; D037181:Lectins, C-Type / Q000235:genetics; D010012:Osteogenesis / Q000187:drug effects*; D053495:Osteopontin; D011509:Proteoglycans / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012795:Sialoglycoproteins / Q000235:genetics; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: D053674:Aggrecans; C546884:BGN protein, human; C525718:BMP2 protein, human; C525819:BMP7 protein, human; D058578:Biglycan; D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D011508:Chondroitin Sulfate Proteoglycans; D050659:Core Binding Factor Alpha 1 Subunit; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D011509:Proteoglycans; D012333:RNA, Messenger; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; D016212:Transforming Growth Factor beta; D053495:Osteopontin; D000469:Alkaline Phosphatase